Synta Pharmaceuticals (SNTA) Said SYMMETRYSM Trial Did Not Achieve Statistical Significance
Tweet Send to a Friend
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced the preliminary results of the Phase 3 SYMMETRYSM trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
